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Atrial Fibrillation
and Thrombosis:
The Missing Molecular Links*
Andrew D. Blann, PHD, Gregory Y. H. Lip, MD
Birmingham, United Kingdom
Nonvalvular atrial fibrillation (AF) confers a 5-fold in-
creased risk of stroke and systemic thromboembolism (TE),
especially in the presence of stroke risk factors (1). AF is
common, and the TE manifestations are evident in many
diverse cardiovascular conditions. For example, transient
new-onset AF in acute myocardial infarction is a risk factor
for stroke (2). Also, patients with left ventricular systolic
impairment with associated AF are at high risk of TE (3).
Fortunately, the use of anticoagulation therapy reduces the
risk of stroke and/or TE (by 64%) as well as all-cause
mortality (by 26%), whereas aspirin results in a nonsignifi-
cant 19% reduction in stroke and/or TE and a nonsignifi-
cant reduction in mortality (4).
See page 852
Intense interest has been directed into the pathophysiol-
ogy of TE in this common arrhythmia. AF may confer a
prothrombotic or hypercoagulable state that fulfills Vir-
chow’s triad for thrombogenesis (5). Attention to the
laboratory has clearly demonstrated the presence of a hy-
percoagulable state in AF patients and the link with both
pathophysiology and anticoagulation. Although there is
evidence of platelet activation in AF, this may not be
significantly more that than seen with the associated vascu-
lar disease or risk factors (6). Of note, thrombus formed in
AF is fibrin-rich (i.e., “red clot”), hence, the effectiveness of
anticoagulation; in contrast, thrombus in acute coronary
syndrome is platelet-rich (i.e., “white clot”), hence, the
effectiveness of antiplatelet therapy (5).
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address issues in large cohorts of those with the disease, and
AF patients may be a heterogeneous group. For example,
data are not necessarily applicable to the individual and
cannot directly attribute cause and effect. Also, other co-
morbidities inevitably present in this group may contribute
to the hypercoagulable state. Given that 1 component of
Virchow’s triad for thrombogenesis in AF is “flow abnor-
malities,” another potential mechanism to explain the link
between cardiac abnormalities and the resultant thrombosis
in AF could be related to rate and rhythm. It is entirely
plausible that abnormalities in either or both of these
processes could be responsible for stroke and/or TE in AF.
In this issue of the Journal, Lim et al. (7) report a study
of 55 patients with a history of AF but who were in sinus
rhythm, in whom they deliberately induced AF in 1 group
of patients (giving mean atrial and ventricular rates of 293
and 108 beats/min, respectively), and paced a second group
to 150 and 115 beats/min, respectively. A control group had
rates of 68 and 66 beats/min, respectively. Although the AF
group clearly had much higher atrial beats per minute than
the pacing group, interesting findings resulted from the
analyses of blood obtained from the left atrium (LA), the
right atrium (RA), and from a peripheral vein before and 15
min after the induction of AF or pacing.
Using established methods for assessing platelet activa-
tion (P-selectin expression) and the generation of thrombin
(thrombin-antithrombin complexes), Lim et al. (7) showed
that induction of AF and paced tachycardia was associated
with (or caused?) increased platelet activation in all 3
samples of blood. In the pacing group, there was more
platelet activation in samples taken from the LA compared
with those from the venous blood. The key control exper-
iment was that platelet expression of P-selectin decreased in
all 3 samples of blood over the 15-min period, possibly
because of the effect of the use of heparin. The situation for
thrombin generation was different; levels increased in the
LA and RA samples from the AF and paced groups, but
decreased in the peripheral sample, whereas levels also
decreased in blood from all 3 sites in the control group. The
decline in thrombin-antithrombin complexes could again be
ascribed to the use of heparin.
The design of this study by Lim et al. (7) is similar to, and
perhaps confirms and notably extends that of Akar et al. (8),
ho reported that induced AF was rapidly associated with
or caused?) increased platelet activation and thrombin
eneration. However, the data by Akar et al. (8) were
enerated in blood taken from the coronary sinus, whereas
he study of Lim et al. (7) crucially took blood from the LA
nd RA, as well as a peripheral sample, allowing the
natomy of the abnormalities to be dissected. Their data
upport the widely held, but unconfirmed perception, that
F may directly cause hypercoagulability in the LA, but
hat it also occurs in the RA.
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presence of localized LA hypercoagulability, but the results
were conflicting (9,10). Another study with intracardiac
direct blood sampling during cardiac surgery suggested
some differences in von Willebrand factor, tissue factor, and
inflammatory biomarker levels between the different cardiac
sampling sites and peripheral artery and/or vein samples,
some of which may be pathophysiologically relevant, for
example, in the development post-operative AF (11). The
increase in thrombin generation in the LA and RA un-
equivocally justifies the use of anticoagulant therapy in AF,
should any be needed.
What are the caveats? The sample size in the study by
Lim et al. (7) was modest, and the sampling time points
were at 15 min, close to (or sometimes less) than the
half-times for concentration change of some of the mea-
sured biomarkers, if elevated. Would the transseptal punc-
ture cause tissue (and endocardial) damage to influence
levels of the measured biomarkers? Other residual con-
founding, such as diurnal differences in these biomarkers, as
well as the impact of comorbidities, are other consider-
ations. Thus, are we measuring a true effect of AF per se, or
simply a physiological variation? More questions remain,
and in trying to understand the complex (and multifactorial)
pathophysiological interactions associated with the pro-
thrombotic state in AF, the missing molecular links still
remain elusive.
What are the clinical implications? The cynic would
argue that because we now have effective treatment modal-
ities to manage AF in a holistic manner (12), does it really
matter if a hypercoagulable state in AF is localized to the
LA (resulting in an increased risk of stroke and/or TE)
and/or whether this is related to rate (or rhythm)? We
should perhaps move away from the continued obsession to
identify perceived “high-risk” features for stroke and/or TE
in AF, because clinical risk factors alone are insufficient
unless biomarkers (whether blood, urine, imaging, echocar-
diographic, and so on) are added, albeit at the price of
reduced simplicity and practicality.
On this exact point, the latest European Society of
Cardiology guidelines now strongly recommend a clinical
practice shift to focus more on the identification of “truly
low-risk” patients who do not need any antithrombotic
therapy, rather than to direct focus on identification of
high-risk patients (13). After the identification of the truly
low risk group (that is, age  65 years and with lone AF, or
CHA2DS2-VASc [congestive heart failure, hypertension,
age 75 years [[doubled]], diabetes, stroke [[doubled]],
vascular disease, age 65 to 74 years, sex category [[female]]
score  0), all other AF patients with 1 stroke risk factors
can be offered effective stroke prevention, which is oral
anticoagulation, whether given as well-controlled adjusted
warfarin or 1 of the novel oral anticoagulant drugs (14,15).
Of note, a CHADS2 score0 is not “low risk” as suchpatients may have a stroke and thromboembolism rate that
varies from 0.8%/year up to 3.2%/year (14).
With this clinical practice change, effective stroke pre-
vention can be considered for most patients with AF, with
important implications for the reduction of fatal and dis-
abling strokes associated with this arrhythmia.
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